Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced the publication of a study in Genetics in Medicine, the official journal of the American College of Medical ...

Peer-reviewed publication examines the benefits of proactive exome reanalysis on diagnostic outcomes Ambry Genetics’ Patient for Life program is supported by a dedicated team of scientists who ...

Tempus AI delivered strong Q1 results, driven by the Ambry Genetics acquisition and a major AstraZeneca contract, boosting revenue and backlog. The AI precision medicine company grew core revenues ...

Tempus AI is delivering explosive growth, driven by its full-stack AI healthtech platform, stellar execution, and strategic acquisitions like Ambry Genetics and Deep 6 AI. Revenues surged 75% year ...

Despite filing a fourth-quarter and year-end 2024 earnings report that the CEO described as "fantastic" yesterday afternoon, Tempus AI shares fell overnight and a major investment house downgraded ...

Tempus AI reports mixed fourth-quarter financial results. JPMorgan analyst Rachel Vatnsdal downgrades Tempus AI from Overweight to Neutral following the company's quarterly results. Ready to turn ...

Key Points About Article Just a few weeks ago, Tempus AI (NASDAQ: TEM) rocketed from about 44% higher.All on news it just acquired Ambry Genetics and on news, Nancy Pelosi took a stake in the TEM ...

Tempus announced its acquisition of Ambry Genetics for $375 million in cash and $225 million in shares at closing in November and the deal closed earlier this month. Ambry will continue to operate ...